Table 3.

Mixed relative treatment effects of composite adverse events and estimated glomerular filtration rate among urate lowering agents

eGFR; MD (95% CI)
Probenecid	-	-	-
0.52 (0.08, 3.52)	Febuxostat	-0.80 (-2.66, 1.05)	2.89 (0.69, 5.09)
0.42 (0.10, 1.73)	0.80 (0.23, 2.82)	Allopurinol	3.69 (1.31, 6.08)
0.68 (0.16, 2.84)	1.30 (0.28, 5.99)	1.63 (0.70, 3.79)	Placebo/no ULT
Adverse events; RR (95% CI)

CI Confidence interval, eGFR Estimated glomerular filtration rates, MD Mean difference, RR Risk ratio, ULT Urate-lowering therapy agents

Comparisons are read from left to right for both eGFR and adverse events. For example; allopurinol had higher adverse events with RR (95% CI) of 1.63 (0.70, 3.79) compared with placebo/no ULT, and higher eGFR with MD (95% CI) of 3.69 (1.31, 6.08) compared with placebo/no ULT

Bold font indicates statistical significance